1910 Genetics launches advanced AI model for blood-brain barrier drug permeability.

1910 Genetics launches CANDID-CNS(TM), an AI model for blood-brain Barrier Permeability prediction that outperforms the industry standard.

BOSTON--(BUSINESS WIRE)--1910 Genetics (or “1910”), the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation, today announced a new five-year commercial agreement and go-to-market collaboration with Microsoft to harness advanced artificial intelligence (AI) and next-generation, high-performance computing (HPC) to reverse 70 years of declining pharmaceutical RD productivity. 1910 will combine its massive computational and wet lab biological data, robotics-driven laboratory automation and multimodal AI models for drug discovery with Microsoft’s HPC platform, Azure Quantum Elements, empowering researchers worldwide with a groundbreaking cloud platform purpose-built at the intersection of AI and HPC to accelerate scientific discovery. 1910 will offer the platform to pharmaceutical, biotechnology, government, academic, and research institutions via three partnership models: Co-discovery, Co-engineering, and Platform-as-a-Service. Potential partners can sign up here for early access